LabCorp launches new age-based test protocol for cervical cancer and STD screening

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) announced today the launch of an innovative age-based test protocol that aids physicians when ordering cervical cancer and sexually transmitted disease (STD) screening tests.    

Through this age-based approach, clinicians can select a test number that will individualize cervical cancer and STD testing based on patient age (from 21-64) and the corresponding age-based test protocol - as set forth in the American Congress of Obstetricians and Gynecologists (ACOG) guidelines.

"This is a novel approach," said Dr. Mark Brecher, LabCorp's Chief Medical Officer. "Offering cervical cancer testing and STD alternatives that follow the ACOG guidelines for age-based testing provides our clients an important tool to assist in providing the best possible patient care."

This enhancement to LabCorp's test menu is an adjunct to its broad women's health test options, including tests that focus on both screening and diagnosis of disease. In addition to its women's health services, LabCorp offers a comprehensive menu of individual tests and test combinations to address specific patient needs.